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Abstract
Cardiovascular disease (CVD) prevention is defi ned as a coordinated set of actions, at the 
population level or targeted at an individual, that are aimed at eliminating or minimizing the 
impact of CVDs and their related disabilities. 1,2In apparently healthy people, CVD risk is usually 
the product of several risk factors. At any given cholesterol or blood pressure (BP) level, risk 
may vary tenfold depending on the presence of other risk factors. Risk is even higher in those 
with established disease. Better control of risk factors, enhanced diagnostic techniques and 
improved medical therapies have all substantially decreased the mortality of CVD in developed 
countries. However, coronary artery disease (CAD) and other forms of atherosclerotic CVD are 
projected to remain the leading cause of death by 2030 and we face a plenty of challenges if 
the outcomes of CVD are to be further improved.3
As a matter of fact, a substantial fraction of high-risk subjects do not reach treatment goals for 
important risk factors is one of these challenges. At the same time, there is also a non-negotiable 
fraction of ‘concealed’ high-risk subjects who are not detected by curent risk algorihtms and 
diagnostic modalities. In recent years, we have started to rapidly increase our knowledge of 
the framework of common genetics underlying CVD in population. In conjuction with modern 
diagnostics and therapeutic options, this new genetic knowledge may provide a valuable tool 
for further improvements in CVD prevention.3
Prevention of CVD, either by implementation of lifestyle changes or use of medication is cost 
effective in many scenarios, including population-based approaches and actions directed at 
high-risk subjects. Cost-effectiveness depends on several factors, including baseline CV risk, 
cost of drugs or other intervention, reimbursement procedures and implementation of preventive 
strategies.1 
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